The regulatory effects of interleukin-12 on interleukin-18 and interferon-γ production in Egyptian breast cancer patients  by Demian, Soheir R. et al.
Alexandria Journal of Medicine (2011) 47, 283–290Alexandria University Faculty of Medicine
Alexandria Journal of Medicine
www.sciencedirect.comORIGINAL ARTICLEThe regulatory eﬀects of interleukin-12 on interleukin-18
and interferon-c production in Egyptian breast
cancer patientsSoheir R. Demian a, Mona Hamdy a, Inas M. Ali b,*a Immunology Department, Medical Research Institute, Alexandria University, Egypt
b Cancer Management and Research, Medical Research Institute, Alexandria University, EgyptReceived 6 June 2011; accepted 17 July 2011
Available online 24 August 2011*
E
20
Pr
Pe
M
doKEYWORDS
Interleukin;
Interferon-cCorresponding author. Mo
-mail address: Inas.el.badry
90-5068 ª 2011 Alexandr
oduction and hosting by Els
er review under responsibilit
edicine.
i:10.1016/j.ajme.2011.07.016
Production and hbile: +20
@hotmai
ia Univ
evier B.V
y of Ale
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world. The outcome of malignant neoplasia in human is often accompanied by defective cellular
immunity.
Objective: To investigate the regulatory effects of IL-12 on IL-18 and IFN-c production in patients
with breast cancer. In addition, the correlations between IL-18 and IFN-c levels with different prog-
nostic factors.
Methods: This study included 40 female patients with histologically proved breast cancer. They
were divided into two groups metastatic and non-metastatic. Peripheral blood mononuclear cells
were isolated from freshly drawn heparinized blood of each subject and cultured with and without
recombinant IL-12 supplementation. IL-18 and IFN-c levels assessed using ELISA before and after
the addition of IL-12.
Results: The level of IL-18 in culture supernatants ranged from 0.69 to 0.95 ng/ml with mean value
of 0.8 ng/ml in non-metastatic patients, whereas IL-18 in metastatic patients levels varied from 0.5
to 0.7 ng/ml with a mean value of 0.6 ng/ml after supplementation with IL-12. In non-metastatic
patients the levels of IFN-c ranged from 1.2 to 1.9 ng/ml with mean value 1.4 ng/ml while in10 6566583.
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ersity Faculty of Medicine.
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284 S.R. Demian et al.metastatic patients the levels ranged from 0.7 to 1.2 ng/ml. Statistical analysis of data revealed that
the supplementation of culture with IL-12 signiﬁcantly increased the mean values of IL-18 IFN-c in
different clinicopathological parameters.
Univariate analysis by age, tumor size, grade, number of lymph nodes, ER-PR, IL-18 level, and
HER2 neu. Indicated that patients with IL-18 level higher than the median at the diagnosis had
higher survival results than those with lower IL-18 concentration. In multivariate analysis IL-18
did not have an independent inﬂuence on the survival.
Conclusion: Findings provide insights that interleukin-12 may be a potent stimulant of the immune
response by enhancing the production of IL-18 and IFN-c. We can suggest that, IL-12 could be
used as a therapeutic agent for improving prognosis associated with breast cancer.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Breast cancer is an important public health problem. It is the
commonest form of cancer in women throughout the world.1
In Egypt, it ranked ﬁrst among malignancies in females, with
incidence of 37.3%.2
Multiple factors are associated with increased risk of its
development. Breast cancer has unpredictable course and char-
acterized by long duration and heterogeneity among patients.
However, there has been decline in breast cancer mortality
overall which is attributed to both success of early detection
programs and advances in treatment.3
Cell mediated immunity plays an important role in the host
defense mechanisms to malignant neoplasia. It is enhanced by
T helper cells and has different effects on the destruction of
malignant cells of the numerous tumor models.4,5
Interleukin-12 (IL-12) and IL-4 induce differentiation of
naı¨ve T cells towards Th1 and Th2 cells, respectively.6
Previous reports demonstrated the shift from Th1 to Th2 in
peripheral blood mononuclear cells (PBMCs) from cancer
bearing patients.7
Malignant neoplasia in humans is often accompanied by
defective cellular immunity.8
There is substantial evidence for immune defects in patients
with breast cancer. They have lower absolute numbers of
peripheral blood lymphocytes,9 but increased numbers of func-
tionally suppressive CD4+ CD25+ Treg.
Studies of these cells and NK cells have revealed molecular
and cellular mechanisms of immunosuppression.10
The prevalence of T (reg) is increased in the peripheral
blood as well as in the tumor microenvironment in patients
with invasive breast cancer. These T (reg) may mitigate the im-
mune response against cancer, and may partly explain the poor
immune response against tumor antigens.11
Interleukin-12 (IL-12) is an important cytokines that induce
the activation of natural killer (NK) cells, T cells and expres-
sion of anti angiogenic genes.12
Decreased IL-12 production may be an important factor
for progressive tumor growth.13 IL-12 has the ability to pro-
duce a distinct sequence of molecular and phenotypic changes
in the tumor leading to anti tumor response.14 It up regulate
Fas expression in human breast cancer cells which plays a role
in the elimination of metastatic tumor activity.15
It was found that IL-12 treatment of a murine model breast
cancer lead to tumor regression and systemic anti tumor
immunity.16Furthermore IL-12 induces naı¨ve CD4+Thelper cells to de-
velop into Th-1 cells in vivo and in vitro. Resting T cells do not
express interleukin-18 receptor (IL-18R) and fail to produce
IFN-c. Pre-treatment of T cells andB cells with (IL-12) rendered
them responsive to IL-18 by activation of STAT4 (a protein in-
side the cell plays an important role in IFN-c production) and
induction of interleukin-18 receptor (IL-18R).17
These IL-12 stimulated cells had both high and low afﬁnity
IL-18R and an increased IL-18R mRNA expression. IL-18
receptor transduces a signal that activates a kinase and conse-
quently explains their important direct effect on IFN-c
production.18
IL-18 is a multifunctional cytokines. It plays an important
role in the manifestations of T cell mediated immunity in cancer
patients through activating natural killer (NK) cells and IFN-c
production by peripheral blood mononuclear cells (PBMC’s)
which exhibits a number of immune regulatory effects.19
Many studies revealed that IFN-c helps to restore the cellu-
lar immunity and shift the balance from Th2 to Th1. Also its
production by T cells and natural killer cells is central to the
scenario of IL-18 induced anti-tumor response.20
Mononuclear cells of patients with breast cancer have a
defective IL-12 and IFN-c production capability while gener-
ating higher amounts of IL-10 and IL-4.21,22 This may explain
why the anti-tumor response to breast cancer is impaired.
Although information is steadily accumulating describing the
functional activities of these cytokines, very few data have
been reported on the regulation of their production.23
Therefore, the characterization of different cytokines pro-
duction is important for investigating the impaired cellular
immunity and the application of immunotherapeutic principles
to treatment of breast cancer.
The aim of this work is to investigate the regulatory effects
of IL-12 on IL-18 and IFN-c production in patients with
breast cancer. In addition, the correlations between IL-18
and IFN-c levels with different prognostic factors were studied
before and after in vitro treatment by IL-12.2. Methods
2.1. Subjects
This study was conducted on 40 female patients with histolog-
ically proved breast cancer. They were divided into two-groups
(metastatic and non-metastatic).
Table 1 Clinicopathological characteristics of patients.
Clinicopathological characteristics Frequency
Non-metastatic Metastatic
No. % No. %
Age (years)
30 2 10 2 10
40 10 50 8 40
50+ 8 40 10 40
v2, p 1.85, 0.56
Menstrual status
Pre-menopausal 12 60 10 50
Post-menopausal 8 40 10 50
v2, p 0.98, 0.71
Tumor grade
Grade II 18 90 14 70
Grade III 2 10 6 30
v2, p 1.250, 0.26
Tumor size
T1 (<2 cm) 2 10 0 0
T2 (2–5 cm) 14 70 12 60
T3 (>5 cm) 4 20 8 40
v2, p 1.744, 0.418
Lymph node status
+ve 16 80.0 20 100.0
ve 4 20.0 0 0.0
v2, p 2.22, 0.13
Number of Lymph node involvement
1–3 2 10.0 10 50.0
4–10 14 70.0 8 40.0
>10 0 0.0 2 10.0
v2, p 6.48, 0.09
Hormonal receptor status
ER
ve 2 10.0 4 20.0
+ (Mild) 10 50.0 4 20.0
++ (Moderate) 4 20.0 8 40.0
+++ (Strong) 4 20.0 4 20.0
v2, p 2.29, 0.51
PR
ve 2 20.0 4 10.0
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search department, Medical Research Institute, Alexandria
University. The study also included 20 healthy age matched fe-
males were taken as a control group.
Between January 2006 and September 2006, 40 patients with
breast cancer presenting and treated in cancer management and
research department, Medical Research Institute were included
in the study and followed for 4 years. Eligibility criteria were
histologically proved breast cancer, adequate hematologic
parameters, normal electrocardiogram, no history of cardiac
problems and no previous chemotherapy, complete hemato-
logic and biochemical studies, assessment of performance status
according to Karnofsky scale, radiological investigation includ-
ing X-ray chest and CT abdomen and pelvis, bone scan. Assess-
ment of estrogen and progesterone receptor as well as HER2
neu was performed by immunohistochemistry.
2.2. Immunological studies
2.2.1. Separation of peripheral blood mononuclear cells
(PBMCs)
PBMCs were isolated from heparinized freshly drawn blood of
each subject under study before treatment by Ficoll-hypaque
density gradient centrifugation.21
2.2.2. Stimulation with IL-12
The separated cells were cultured either alone or with the opti-
mum dose of recombinant IL-12 r (IL-12) for 72 h at 37 C and
5% CO2 atmosphere. The culture supernatants isolated and
stored at 70 C until cytokines assay.
2.2.3. IL-18 and IFN-c immunoassay
IL-18 and IFN-c levels in culture supernatant of each sample
were assayed before and after the addition of IL-12 using en-
zyme linked immune absorbent assay (ELISA).22
2.3. Survival analysis
Actuarial curves of overall survival were obtained according to
Kaplan–Meier method. Comparison between curves were
made using log rank test.+ (Mild) 6 30.0 6 30.0
++ (Moderate) 8 40.0 8 40.0
+++ (Strong) 4 10.0 2 20.0
v2, p 0.67, 0.82
HER2 neu
Positive 4 20 7 35
Negative 16 80 13 65
v2, p 0.57, 0.723. Results
3.1. Clinical assessment
Patient’s characteristics are summarized in Table 1.
3.2. Immunological results
3.2.1. IL-18 assay
The mean value of IL-18 in culture supernatants of the normal
controls before IL-12 supplementation was 1.44 ± 0.16 ng/ml
while it was 0.80 ± 0.10 and 0.61 ± 0.07 ng/ml in non-meta-
static and metastatic, respectively (Table 2).
After IL-12 supplementation, the mean value of IL-18 in
normal controls was 2.72 ± 0.28 ng/ml while, it was
1.4 ± 0.21 and 0.95 ± 0.14 ng/ml in non-metastatic and meta-
static patients, respectively (Table 2).The percent of change (stimulation%) in IL-18 levels in-
duced by IL-12 supplementations in the culture supernatants
of the normal controls (88.89%), non-metastatic patients
(76.25%) and metastatic group (55.7%) showed a signiﬁcant
increase in the IL-18 levels after IL-12 supplementation
(Fig. 1).
3.2.2. INF-c assay
Regarding IFN-c levels, it was observed that its mean value in
the culture supernatants of normal controls was
Table 2 IL-18 levels (ng/ml) in culture supernatant of normal
controls, non-metastatic and metastatic patients with breast
cancer before and after stimulation with IL-12.
Control
‘‘gp. I’’
Non-metastatic
‘‘gp. III’’
Metastatic
‘‘gp. II’’
Before
Range 1.16–1.64 0.69–0.95 0.5–0.7
Mean 1.44 0.80 0.61
SD 0.16 0.10 0.07
F 137.78
p 0.0001
After
Range 2.3–3.10 1.2–1.9 0.75–1.20
Mean 2.72 1.41 0.95
SD 0.28 0.21 0.14
F 176.733
p 0.0001
Table 3 IFN-c levels (pg/ml) in culture supernatant of normal
controls, non-metastatic and metastatic patients with breast
cancer before and after stimulation with IL-12.
Control Non-metastatic Metastatic
Before
Range 12–22 3.0–8.0 2.0–6.0
Mean 15.70 5.00 3.70
SD 3.09 1.49 1.34
F 95.811
p 0.00001
After
Range 22.0–45.0 6.0–15.0 4.0–8.0
Mean 31.80 9.30 6.30
SD 8.85 2.91 1.34
F 65.740
p 0.0001
286 S.R. Demian et al.15.70 ± 3.09 pg/ml whereas it was 5.00 ± 7.44 and
0.70 ± 1.34 pg/ml in non-metastatic and metastatic patients,
respectively. However after IL-12 supplementation the mean
value of IFN-c was 31.8 ± 8.85 pg/ml while it was
9.30 ± 2.91 and 6.3 ± 1.34 pg/ml in non-metastatic and meta-
static patients, respectively (Table 3).
Concerning the percent of change (stimulation %) in the
IFN-c levels, it was observed that the % change in the nor-
mal controls was 102.55% and in non-metastatic patients
was 86.00%. Whereas, in the metastatic patients it was
70.70% indicating a signiﬁcant increase (p= 0.00001) in
the IFN-c levels induced by IL-12 supplementation
(Fig. 2).
3.2.3. IL-18 and IFN-c and clinico-pathological ﬁndings
Statistical analysis of our data revealed a signiﬁcant decrease
in the mean values of IL-18 as well as of IFN-c in the dif-
ferent clinicopathological parameters (large tumor size, neg-
ative hormone receptor status, positive HER2 neu, and hight
grade tumor in both metastatic and non-metastatic.
3.2.4. Correlation analysis in non-metastatic patients
Our data showed, signiﬁcant positive correlations between IL-
18 levels before and after supplementations with IL-12Normal Non-metas
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Figure 1 The mean values and the percent change (stimulation %) of
metastatic and metastatic patients with breast cancer.(r= 0.85, p= 0.001) and also between IL-18 before supple-
mentation and the level of IFN-c after supplementation with
IL-12 (r= 0.63, p= 0.023). Besides, after IL-12 supplementa-
tion there was a signiﬁcant positive correlation between the le-
vel of IL-18 and IFN-c (r= 0.58, p= 0.031). Moreover, there
was a signiﬁcant positive correlation was indicated between
IFN-c before and after supplementation with IL-12
(r= 0.64, p= 0.01) (Table 4).
As regards, correlation analysis in metastatic patients with
breast cancer, it showed a signiﬁcant positive correlation be-
tween IL-18 levels before and after supplementation with IL-
12 (r= 0.79, p= 0.002). Also, there was a signiﬁcant positive
correlation between the levels of IL-18 before supplementation
and IFN-c levels after supplementation (r= 0.70, p= 0.011).
After IL-12 supplementation, there was a signiﬁcant positive
correlation between IL-18 and IFN-c levels (r= 0.61,
p= 0.025). Also, there was a signiﬁcant positive correlation
between IFN-c before and after supplementation with IL-12
(r= 0.74, p= 0.005). In addition, there were non-signiﬁcant
correlations were observed between the other parameters of
the metastatic patients (Table 5).
3.2.5. Survival and IL-18
0.8 ng/ml was considered as cut off value for non-metastatic
and 0.6 ng/ml for metastatic breast cancer patients.tatic Metastatic
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Figure 2 The mean values and the percent change (stimulation %) of INF-c (pg/ml) in the culture supernatants of normal controls, non-
metastatic and metastatic patients with breast cancer.
Table 4 Correlation analysis between IL-18 and IFN-c levels
in culture supernatants of non-metastatic patients with breast
cancer before and after stimulation with IL-12.
IL-18 before stimulation IL-18 after
stimulation
IFN-c before
stimulation
IL-18 after stimulation
r 0.85
p 0.001*
IFN-c before stimulation
r 0.25 0.33
p 0.25 0.19
IFN-c after stimulation
r 0.63 0.58 0.64
p 0.01* 0.038* 0.046*
* Signiﬁcant at p< 0.05.
Table 5 Correlation analysis between IL-18 and IFN-c levels
in culture supernatants of metastatic patients with breast cancer
before and after stimulation with IL-12.
IL-18 before stimulation IL-18 after
stimulation
IFN-c before
stimulation
IL-18 after stimulation
r 0.79
p 0.002*
IFN-c before stimulation
r 0.19 0.41
p 0.45 0.11
IFN-c after stimulation
r 0.70 0.61 0.74
p 0.011* 0.025* 0.005*
* Signiﬁcant at p< 0.05.
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IL-18 level higher than 0.8 ng/ml was 70% versus 45% for
those having IL-18 concentration less than 0.8 ng/ml (Fig. 3).
In metastatic breast cancer the overall survival of patients
with IL-18 level higher than 0.6 ng/ml was 30% versus 10%for those having IL-18 concentration less than 0.6 ng/ml
(Fig. 4).
In univariate analysis by age, tumor size, tumor grade,
number of lymph nodes, ER-PR, IL-18 level, and HER2
neu. It was found that patients with IL-18 level higher than
8 ng/ml at the time of diagnosis had higher survival than those
with lower IL-18 concentration (70% versus 45%) in non-met-
astatic and (30% and 10%) for metastatic breast cancer
patients.
In multivariate analysis IL-18 did not have an independent
inﬂuence on the survival.
4. Discussion
Breast cancer like other malignancies results from stepwise ge-
netic alteration of host cells and non-genetic changes in the
behavior of not only malignant but also host cells that interact
with the tumor such as immune alterations.7
Previous reports have indicated that outcome of malignant
neoplasia in human is often accompanied by defective cellular
immunity. To induce more effective antitumor immune-reac-
tion, increasing the production of Th1-cytokines is needed.
T-helper type I (Th-1) cells promote cellular immunity through
increased interferon-c production. Therefore, cytokine kinetics
may represent a mirror of the immunologic phenomena occur-
ring in the tumor micro-environment, where immune and
malignant cells interact. Yet, cytokines are currently used in
a clinical setting to polarize the immune response against
cancer.
Despite the large amount of information available on im-
mune system physiology, little is known about the role of cyto-
kines in modulating the effectiveness of immunotherapy, and
the clinical trials aimed the treatment of patients with
cancer.15,16
Interleukin-12 is an important cytokine that induce the acti-
vation of natural killer (NK) cells, and T cells. It induces naı¨ve
CD4+ T helper cells to develop into Th1 cells in vivo and
in vitro. Pretreatment of T cells and B cells with IL-12 rendered
them responsive to IL-18.13
Interferon-c production by T- and NK cells is central to the
scenario of the IL-18 induced anti-tumor cascade reaction.16
Thus assessing the capacity of PBMCs in cancer patients to
produce IFN-c as well as IL-18 in response to IL-12, would
be important for investigating the impaired cellular immunity
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Figure 3 Overall survival in non-metastatic breast cancer patients.
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288 S.R. Demian et al.and the application of immunotherapeutic principles to the
treatment of breast cancer.
The results of the present study revealed that the levels of
IL-18 were signiﬁcantly decreased (p= 0.0001) in non-meta-
static (0.80 ± 0.10 ng/ml) and metastatic (0.61 ± 0.07 ng/ml)
patients with breast cancer than normal controls
(1.44 ± 0.16 ng/ml) before stimulation with IL-12.
The impairment in the production of this cytokine can be
explained by the results of Campoli et al.8 who clearly demon-
strated that, progressively growing tumors impair the adaptive
immune response by blocking the maturation and function of
antigen presenting cells and causing alterations in T cell signal
transduction and function. The antigen presenting cells are the
main cells which produce IL-18.
In agreement with our data, Blanck et al.21 Found that dif-
ferentiated monocytes from breast cancer patients are defective
in IL-18 production.
In addition, the ﬁndings of Frydecka et al.22–24 supported
the obtained data as they demonstrated impaired IL-18
responsiveness in peripheral blood mononuclear cells from
cancer-bearing patients. The underlying mechanism for thisimpairment was, at least in part, ascribed to a dramatic de-
crease of natural killer (NK) cells and cytotoxic T-lymphocytes
(CTL) which constitutively and highly express IL-18 receptor
(IL-18R) and also attributed to null production of IL-12 which
up-regulates IL-18.
The current study indicated that, there is a signiﬁcant
(0.00001) decrease in the mean values of IFN-c in non-meta-
static (5.00 ± 1.49 pg/ml) and metastatic (3.70 ± 3.09 pg/ml)
patients with breast cancer compared to normal controls
(15.70 ± 3.09 ng/ml).
This suppression of IFN-c production is indicated by the
observation of Satthapom et al.25 They revealed that the
immune-regulatory CD4(+) CD25(+) T cells have a role in
the suppression of anti-tumor immunity in cancer patients.
Besides, this impairment of immune response associated
with cancer is consistent with the ﬁndings of Blanck,21 who re-
ported that the presence of classical tumor suppressor proteins,
which regulate tumor cell immune function genes, as well as tu-
mor cell mutations that eliminate MHC class I expression af-
fect the anti-tumor immune response. In addition, Pockaj
et al.26 found that reduced T cell and dendritic cell (producers
The regulatory effects of interleukin-12 on interleukin-18 and interferon-c production 289of IFN-c and IL-18, respectively) function is related to cyclo-
oxygenase-2 over expression and prostaglandin E2 secretion in
patients with breast cancer. This adds further explanation to
the decreased production of IFN-c and IL-18 in those patients.
On the other hand, our results demonstrated that when the
culture was supplemented with IL-12, which is a major im-
mune-regulatory cytokine and a key component in numerous
immune functions, there was a signiﬁcant increase in the levels
of IL-18 as well as IFN-c production in each group under
study.
The obtained results are coincided with many investigators
who reported that IL-12 is a critical cytokine that is required
for the promotion of Th1 development as well as IFN-c
production.
Other investigators stated that the primary functions of IL-
18 included the induction of IFN-c production in T- and NK-
cells, which agree with our results.
Similarly, it was reported that IL-12 administration in-
creased the circulating as well as liver associated levels of IL-
18 in wild type mice. IL-12 and IL-18 regulate each other’s
production. IL-18 contributes to induction of IFN-c by IL-
12.27 These data are consistent with our ﬁndings.
Furthermore, our ﬁndings are parallel to the study of Tom-
inga et al.28 who demonstrated that IL-18 by itself can not
stimulate human T cells to produce IFN-c. However, once hu-
man T cells are activated with IL-12, they expressed IL-18 Ra
and produce IFN-c in response to IL-18. It was documented
that IL-12 can induce the production of IL-18 and has a syn-
ergistic effect with IL-18 on the activation of natural killer
(NK) and cytotoxic T-lymphocytes.
Our work also found that there is non-signiﬁcant difference
between the mean values of IL-18 and the different clinico-
pathological characteristics in non-metastatic patients with
breast cancer before stimulation with IL-12 as well as in met-
astatic patients after stimulation with IL-12.
However, after supplementation with IL-12 there is a signif-
icant decrease (p= 0.041) in the mean values of IL-18 in non-
metastatic patients in grade III than those in grade II due to
disease regression.
Regarding IFN-c levels in different clinicopathological
parameters, our study revealed a signiﬁcant decrease
(p= 0.21) in the mean values of IFN-c in non-metastatic pa-
tients with ageP50 years than those <50 years and also in pa-
tients with tumor size >5 cm than those with tumor size
<5 cm before supplementation with IL-12. Whereas, a signif-
icant increase (p= 0.01) in the mean values of IFN-c was ob-
served in patients with (+++) ER/PR compared to those
with (++), (+), and () ER/PR after IL-12 supplementation.
As for the metastatic patients our results indicated a signif-
icant decrease (p= 0.041) in the mean values of IFN-c in pa-
tients with grade III than those in grade II as well as in patients
with tumor size >5 cm than those with tumor size <5 cm.
However, the mean values of IFN-c were signiﬁcantly in-
creased (p= 0.021 and 0.031) in patients with (+++) ER/
PR compared to patients with (++), (+), and () ER/PR
after supplementation with IL-12.
These data clearly indicated that levels of IL-18 and IFN-c
were signiﬁcantly decreased in breast cancer patients who have
a biologically aggressive disease.
The correlation studies in the present work showed signiﬁ-
cant positive correlation was existed between the mean values
of IL-18 and IFN-c production before and after supplementa-tion with IL-12 in all subjects under study denoting that the
signiﬁcant increase in IL-18 levels is associated with signiﬁcant
increase in IFN-c production.
In addition, our correlations also revealed that the supple-
mentation of cultures with IL-12 signiﬁcantly increases the
mean values of both IL-18 and IFN-c in all studied groups,
conﬁrming the previously mentioned data.
In this context, Segel et al.29 reported that IL-12 has a role
in the rejection of established tumors, which dependent on the
induction of a Th1 response producing IFN-c that acts on host
cells.
Other study by Boehm et al.30 demonstrated that IL-12 and
IL-18 synergize to enhance IFN-c production in human T cells
and NK cells.
In addition, it was documented that IL-12 directly up-
regulated the expression of Fas (CD95, APO-1), a cell surface
molecule capable of inducing ligand-mediated apoptosis, on
human breast cancer cells which plays a role in the elimination
of metastatic tumor activity. The mechanism underlying this
anti-tumor activity may be related to its ability to inhibit angi-
ogenesis. Other investigators showed that IL-12 primes macro-
phages for nitric oxide production which is involved in
mechanisms that control tumor growth in animal models.
Moreover, it was found that IL-12 treatment of a murine
model breast cancer lead to tumor regression and systemic
anti-tumor immunity.31–33
From our ﬁndings we can conclude that: Interleukin-12
plays a crucial role in the improvement of impaired immunity
by induction of Th1 response in patients with breast cancer. It
is a potent stimulant of the immune response by enhancing the
production of IL-18 and IFN-c. Consequently, we can suggest
that, IL-12 can be used as a therapeutic agent for correction of
the immunodeﬁciency associated with malignancy. It can be an
effective weapon against cancer, but it can also cause toxic
complications that interfere with its use. Therefore, its
clinical safety and usefulness have to be proven in additional
studies.
Appendix A. Treatment protocol
A.1. Chemotherapy
All non-metastatic patients were planned to receive six cycles of
FAC regimen. Flourouracil 600 mg/m2 IV/D1, Adriamycin
60 mg/m2 IV/D1, Endoxan 600 mg/m2 IV/D1. Cycles were re-
peated every 21 days and all patients received the total of 6
courses of treatment. Docetaxel and Cisplatin as ﬁrst line treat-
ment in metastatic patients previously treated with Adriamycin,
Cisplatin 75 mg/m2 IV 2 h infusion, Docetaxel 75 mg/m2 IV 1 h
infusion. Cycles were repeated every 3 weeks-carboplatin was
substituted for Cisplatin in the event of renal toxicity.
Patients received pre medication with Dexamethasone
(20 mg IV) cimetidine (200 mg IV) and other antihistaminic
drugs just before Docetaxel administration. Patients with sta-
ble disease, partial response or complete response receive the
combination until they developed progressive disease.
A.2. Hormonal treatment
Nolvadex: All patients with positive ER and PR receptor re-
ceived Nolvadex (10 mg) 2 tablets per day for 5 year.
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